Early-Stage HCC Percutaneous Locoregional Management: East versus West Perspectives-Reference-Cited by-同舟云学术

Early-Stage HCC Percutaneous Locoregional Management: East versus West Perspectives

Published:2023-08-06 Issue:15 Volume:15 Page:3988
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Iezzi Roberto¹²^ORCID,Posa Alessandro¹,Contegiacomo Andrea¹,Lee In Joon³,Bale Reto⁴^ORCID,Tanzilli Alessandro⁵,Tenore Lorenzo¹,Giuliante Felice²⁶,Gasbarrini Antonio²⁷,Goldberg Shraga Nahum⁸^ORCID,Jakobs Tobias⁹^ORCID,Pompili Maurizio²⁷,Bargellini Irene¹⁰,Sala Evis¹²,Kim Hyo-Cheol¹¹

Affiliation:

1. Department of Diagnostic Imaging, Oncologic Radiotherapy and Hematology, A. Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy

2. School of Medicine, Catholic University of the Sacred Heart, 00168 Rome, Italy

3. Department of Radiology, National Cancer Center, Goyang 10408, Republic of Korea

4. Section of Interventional Oncology-Microinvasive Therapy (SIP), Department of Radiology, Medical University of Innsbruck, 6020 Innsbruck, Austria

5. Department of Radiology, Santa Maria Goretti Hospital, 04100 Latina, Italy

6. Hepatobiliary Surgery Unit, A. Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy

7. Internal Medicine and Gastroenterology Unit, A. Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy

8. Division of Image-Guided Therapy, Department of Radiology, Hadassah Hebrew University Medical Center, Jerusalem 91120, Israel

9. Clinic of Interventional Radiology, Hospital Barmherzige Brueder, 93049 Munich, Germany

10. Institute of Radiology, Candiolo Hospital, 10126 Turin, Italy

11. Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea

Abstract

Hepatocellular carcinoma represents an important cause of death worldwide. Early-stage hepatocellular carcinoma patients not suitable for surgery can be treated with a variety of minimally invasive locoregional interventional oncology techniques. Various guidelines in different countries address the treatment of hepatocellular carcinoma, but the actual treatment is usually discussed by a multidisciplinary tumor board in a personalized manner, leading to potential treatment differences based on Western and Eastern perspectives. The aim of this paper is to integrate literature evidence with the eminent experiences collected during a focused session at the Mediterranean Interventional Oncology (MIO) Live Congress 2023.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

https://www.mdpi.com/2072-6694/15/15/3988/pdf

Reference56 articles.

1. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification;Fisher;Adv. Cancer Res.,2021

2. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons;Makary;World J. Gastroenterol.,2021

3. Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments;Gnutzmann;Minim. Invasive Ther. Allied Technol.,2018

4. Image-Guided Ablation of Malignant Liver Tumors: Recommendations for Clinical Validation of Novel Thermal and Non-Thermal Technologies—A Western Perspective;Lencioni;Liver Cancer,2015

5. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update;Reig;J. Hepatol.,2022